
Medpace Holdings MEDP
$ 428.0
-0.26%
Quarterly report 2026-Q1
added 04-23-2026
Medpace Holdings Gross Profit 2011-2026 | MEDP
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Medpace Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 246 M | 216 M | 175 M | 172 M | 156 M | - | 124 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 246 M | 124 M | 181 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | ||
|
Agilent Technologies
A
|
2.84 B | $ 115.84 | 0.68 % | $ 35.2 B | ||
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
400 K | $ 7.3 | -19.87 % | $ 9.71 M | ||
|
Castle Biosciences
CSTL
|
53 M | $ 21.26 | 7.97 % | $ 616 M | ||
|
Aspira Women's Health
AWH
|
5.92 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
2.7 M | - | -61.36 % | $ 2.46 M | ||
|
Fulgent Genetics
FLGT
|
131 M | $ 17.9 | 1.3 % | $ 551 M | ||
|
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | ||
|
Guardant Health
GH
|
144 M | $ 127.51 | 6.39 % | $ 16 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
81.6 M | $ 22.16 | 2.88 % | $ 1.18 B | ||
|
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | ||
|
Interpace Biosciences
IDXG
|
24.1 M | $ 1.8 | - | $ 7.96 M | ||
|
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
817 M | $ 118.45 | 4.04 % | $ 9.77 B | ||
|
Illumina
ILMN
|
2.86 B | $ 150.17 | 3.41 % | $ 23.9 B | ||
|
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | ||
|
Lantheus Holdings
LNTH
|
942 M | $ 99.09 | -0.97 % | $ 6.69 B | ||
|
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-240 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | ||
|
Mettler-Toledo International
MTD
|
2.39 B | $ 1 093.84 | -0.68 % | $ 22.5 B | ||
|
Charles River Laboratories International
CRL
|
958 M | $ 164.49 | 4.95 % | $ 8.15 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | ||
|
NeoGenomics
NEO
|
314 M | $ 9.57 | 3.24 % | $ 1.23 B | ||
|
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | ||
|
National Research Corporation
NRC
|
81.5 M | $ 19.13 | 0.47 % | $ 428 M | ||
|
Natera
NTRA
|
127 M | $ 203.11 | 1.1 % | $ 20 B | ||
|
Exact Sciences Corporation
EXAS
|
2.26 B | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
577 M | $ 3.94 | 2.34 % | $ 365 M | ||
|
Personalis
PSNL
|
22.1 M | $ 9.49 | 6.15 % | $ 847 M | ||
|
Koninklijke Philips N.V.
PHG
|
8.06 B | $ 26.6 | -1.26 % | $ 25.2 B | ||
|
Senseonics Holdings
SENS
|
15.8 M | $ 6.32 | -1.71 % | $ 264 M | ||
|
QIAGEN N.V.
QGEN
|
1.3 B | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
-58.5 K | - | - | $ 2.69 B | ||
|
Twist Bioscience Corporation
TWST
|
6.96 M | $ 64.17 | -1.08 % | $ 3.84 B | ||
|
Biomerica
BMRA
|
498 K | $ 2.46 | -0.61 % | $ 5.65 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4.01 B | $ 258.25 | -0.08 % | $ 21.5 B | ||
|
Thermo Fisher Scientific
TMO
|
11.3 B | $ 456.21 | 1.79 % | $ 172 B | ||
|
Waters Corporation
WAT
|
1.4 B | $ 342.18 | 1.05 % | $ 20.4 B | ||
|
Trinity Biotech plc
TRIB
|
21.4 M | $ 0.68 | 5.04 % | $ 244 M | ||
|
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
421 M | $ 9.2 | 0.66 % | $ 2 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 193.99 | 0.58 % | $ 21.5 B |